Bioheart bulks up management team
This article was originally published in Clinica
Executive Summary
Several board members of Bioheart, a specialist in cell-based therapies for treating heart disease, have joined the Sunrise, Florida company's management team. Chairman Karl Groth has assumed the additional role of CEO; Peggy Farley is now chief operating officer; and Mark Borman is chief financial officer. In order to focus on building the company's technologies, Bioheart founder Howard Leonhardt has resigned as director, but will continue as chief scientific and technology officer, and chairman of the scientific advisory board. Dr Groth's experience includes helping to establish Medtronic's neuro division and leading several start-up companies to successful exits. These include InStent, which was bought by Medtronic, and Heart Technology, which was acquired by Boston Scientific. Ms Farley comes from an investment banking background and she has been working with Dr Groth since 1999 to build venture capital firm the Ascent Group. Mr Borman has worked as CFO in several technology companies, including ADC Telecommunications and General Instrument.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.